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Background 
Cilostazol and isosorbide mononitrate (ISMN) have effects that may be beneficial in 
patients with cerebral small vessel disease and lacunar ischaemic stroke. We assessed 
their haemodynamic effects in the lacunar intervention-1 (LACI-1) trial. 
 
Methods 
Patients with lacunar ischaemic stroke were randomised to immediate ISMN, cilostazol, 
or their combination for 9 weeks. A fourth group received both drugs but with a delayed 
start. Peripheral blood pressure (BP) and heart rate (HR), and central haemodynamics 
(central BP, Augmentation index [AI] unadjusted and normalised to HR 75bpm, Buckberg 
index [BI], pulse wave velocity [PWV] were measured using the Sphygmacor) at 
baseline, and weeks 3 and 8. Haemodynamic differences were assessed by multiple 
linear regression adjusted for baseline.   Data are mean difference (MD) with 95% 
confidence intervals (CI). 
 
Results 
We recruited 57 patients; those allocated cilostazol alone were older but otherwise the 
groups were well-balanced at baseline. At week 8, BP did not differ between the 
treatment groups, whilst HR was significantly higher in those taking cilostazol vs. no 
cilostazol (MD 6.42, 95% CI 1.17-11.68, p=0.017). BI (subendocardial perfusion) was 
significantly lower in those randomised to cilostazol vs. no cilostazol and in those 
randomised to both drugs vs. either drug. There was a tendency towards reduced AI 
(arterial stiffness) adjusted for HR in those taking cilostazol vs. no cilostazol and ISMN 
vs. no ISMN. 
 
Conclusions 
In patients with lacunar ischaemic stroke, cilostazol increased HR (a recognised effect) 
which may account for the reduced BI; both agents may reduce arterial stiffness. Larger 
trials are warranted. 
 
 
